ECSP20022447A - Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos - Google Patents

Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos

Info

Publication number
ECSP20022447A
ECSP20022447A ECSENADI202022447A ECDI202022447A ECSP20022447A EC SP20022447 A ECSP20022447 A EC SP20022447A EC SENADI202022447 A ECSENADI202022447 A EC SENADI202022447A EC DI202022447 A ECDI202022447 A EC DI202022447A EC SP20022447 A ECSP20022447 A EC SP20022447A
Authority
EC
Ecuador
Prior art keywords
obtaining
composition containing
useful
umbilical cord
population
Prior art date
Application number
ECSENADI202022447A
Other languages
English (en)
Inventor
Paula Montoya
Diego Castro
Khoury Maroun
Francisco Espinoza
Paz González
Jorge Bartolucci
Fernando Figueroa
Jimena Cuenca
Original Assignee
Cells For Cells S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cells For Cells S A filed Critical Cells For Cells S A
Publication of ECSP20022447A publication Critical patent/ECSP20022447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invención proporciona un método para obtener una población específica de células mesenquiales de cordón umbilical. Una composición que contiene esta población de células específicas es útil para preparar un medicamento que sirve para terapias celulares, tales como problemas del flujo de eyección cardiaco de pacientes con una fracción de eyección disminuida. Al mismo tiempo, esta subpoblación es útil para preparar un medicamento que sirve para aliviar el dolor y recuperar la funcionalidad del desgaste en articulaciones; para tratar problemas respiratorios, tales como lesiones pulmonares, lesiones pulmonares agudas, tales como el síndrome de distrés respiratorio agudo y para tratar lesiones cutáneas, tales como heridas crónicas y úlceras.
ECSENADI202022447A 2017-09-16 2020-04-15 Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos ECSP20022447A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017002357A CL2017002357A1 (es) 2017-09-16 2017-09-16 Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos

Publications (1)

Publication Number Publication Date
ECSP20022447A true ECSP20022447A (es) 2020-09-30

Family

ID=63046513

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202022447A ECSP20022447A (es) 2017-09-16 2020-04-15 Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos

Country Status (11)

Country Link
US (1) US20200297778A1 (es)
EP (1) EP3683305A4 (es)
JP (1) JP7218947B2 (es)
CN (1) CN111630156A (es)
BR (1) BR112020005017A2 (es)
CL (1) CL2017002357A1 (es)
CO (1) CO2020004383A2 (es)
EC (1) ECSP20022447A (es)
MX (1) MX2020002822A (es)
PE (1) PE20201347A1 (es)
WO (1) WO2019051623A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
CN110101874A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 一种利用hgf转基因的干细胞治疗ards的方法
CA3170255A1 (en) * 2020-03-05 2021-09-10 Silviu Itescu Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN111840577B (zh) * 2020-05-09 2022-09-13 新乡医学院 一种提高ucmsc肺部输送效率的方法
CN112522193B (zh) * 2020-12-25 2023-03-21 博雅干细胞科技有限公司 无血清培养基在分离和传代脂肪间充质干细胞中的用途
CN114317421B (zh) * 2021-12-16 2024-05-03 北京科技大学 强化间充质干细胞促进血管生成的方法、组合物及应用
CN114159469A (zh) * 2021-12-20 2022-03-11 杭州易文赛生物技术有限公司 一种脐带间充质干细胞在制备修复海马神经元缺氧损伤的药物中的用途
CN116474000B (zh) * 2023-06-20 2023-09-19 北京中卫医正科技有限公司 脐带间充质干细胞制剂、制备方法及其在治疗膝骨关节炎中的应用
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071778A2 (en) * 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
US20080050347A1 (en) * 2006-08-23 2008-02-28 Ichim Thomas E Stem cell therapy for cardiac valvular dysfunction
EP2524034A1 (en) * 2010-01-14 2012-11-21 Organogenesis, Inc. Bioengineered tissue constructs and methods for producing and using thereof
WO2013067038A1 (en) * 2011-11-01 2013-05-10 Neostem, Inc. Adult mesenchymal stem cell (msc) compositions and methods for preparing the same
HK1202581A1 (en) * 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US10724005B2 (en) * 2012-09-28 2020-07-28 Scripps Health Methods of differentiating stem cells into chondrocytes
CN103263440A (zh) * 2013-02-08 2013-08-28 周胜利 从胎盘、脐带中提、制同源性间充质干细胞注射剂的方法
US11179420B2 (en) * 2016-04-27 2021-11-23 Rohto Pharmaceutical Co., Ltd. Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject

Also Published As

Publication number Publication date
JP7218947B2 (ja) 2023-02-07
EP3683305A1 (en) 2020-07-22
JP2020533011A (ja) 2020-11-19
PE20201347A1 (es) 2020-11-30
WO2019051623A1 (es) 2019-03-21
CL2017002357A1 (es) 2018-04-20
BR112020005017A2 (pt) 2020-09-15
CN111630156A (zh) 2020-09-04
US20200297778A1 (en) 2020-09-24
MX2020002822A (es) 2020-10-12
CO2020004383A2 (es) 2020-04-24
EP3683305A4 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
ECSP20022447A (es) Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
ZA202007149B (en) High elasticity hyaluronan compositions and methods of use thereof
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2016001794A1 (es) Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
PH12017500392A1 (en) Medical treatments based on anamorelin
CL2019003484A1 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2021009383A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
CL2025003984A1 (es) Semaglutida en terapia médica.
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras